Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
Publication|Articles|October 24, 2025
- Fall 2025
- Volume 19
- Issue 2
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
This quiz was created in collaboration with PTCE™.
Advertisement
A patient comes to the pharmacy and picks up a new prescription for atorvastatin 20 mg once daily. The patient asks you if there is anything to keep in mind while on this medication. Which is the best response?
Articles in this issue
5 months ago
Spring 2026 Quiz: Test Your Pharmacy Knowledge!11 months ago
A Silent Struggle Behind the White Coat11 months ago
From Stigma to Breakthrough: Psychedelic MedicineAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Harnessing the Gut Microbiome for Enhanced CAR T Cell Therapy
5